Nobuko Hijiya (Children's Hospital of Chicago, Chicago, IL, USA) presented results from a phase 2 study of 58 patients aged 1–18 years with chronic myeloid leukaemia treated with oral nilotinib (230 mg/m² twice a day) in 28-day cycles. Of 33 patients who had previously received imatinib or dasatinib, 13 (39·4%, 95% CI 22·9–57·9) achieved a major molecular response after six cycles of treatment. Median molecular response was achieved in 16 (64·0%; 95% CI 42·5–82·0) of 25 treatment-naive patients after 12 cycles of treatment.

中文翻译：

---

第49届SIOP大会

信子Hijiya（芝加哥的儿童医院，芝加哥，IL，USA）从年龄1-18岁，慢性粒细胞白血病与口服尼罗替尼（230毫克/米治疗的58例患者的相位2研究中提出的结果²，一天两次）在28-日周期。在先前接受伊马替尼或达沙替尼的33位患者中，有13位（39·4％，95％CI 22·9–57·9）在六个疗程后达到了主要的分子反应。经过12个疗程的25例未接受过治疗的患者中，有16位（64·0％; 95％CI 42·5–82·0）获得了中位分子反应。